Job title: CMO
Dr. Mannick is Chief Medical Officer of resTORbio, a clinical stage biotechnology company that is a spin-out of Novartis and developing medicines that target the biology of aging to treat or prevent aging-related diseases. Prior to joining resTORbio, Dr. Mannick was an Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research.
Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology.
Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program. She is board-certified in Internal Medicine and Infectious Diseases.
Targeting the Biology of Aging to Prevent or Treat Aging-Related 9:40 am
day: Day One